COCP - Cocrystal Pharma, Inc.

1.065
0.035   3.286%

Share volume: 55,046
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$1.03
0.03
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.45%
1 Month
11.57%
3 Months
0.47%
6 Months
-26.04%
1 Year
-35.84%
2 Year
-28.04%
Key data
Stock price
$1.06
P/E Ratio 
0.00
DAY RANGE
$1.04 - $1.07
EPS 
-$1.11
52 WEEK RANGE
$0.86 - $2.67
52 WEEK CHANGE
-$34.86
MARKET CAP 
12.824 M
YIELD 
N/A
SHARES OUTSTANDING 
13.784 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$37,926
AVERAGE 30 VOLUME 
$39,867
Company detail
CEO: Sam Lee
Region: US
Website: cocrystalpharma.com
Employees: 10
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cocrystal Pharma, Inc. focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection.

Recent news